JP7436145B2 - Ｃａｓ９ヌクレアーゼをコードする核酸の食餌コントロール発現及びその使用 - Google Patents

Ｃａｓ９ヌクレアーゼをコードする核酸の食餌コントロール発現及びその使用 Download PDF

Info

Publication number
JP7436145B2
JP7436145B2 JP2018563152A JP2018563152A JP7436145B2 JP 7436145 B2 JP7436145 B2 JP 7436145B2 JP 2018563152 A JP2018563152 A JP 2018563152A JP 2018563152 A JP2018563152 A JP 2018563152A JP 7436145 B2 JP7436145 B2 JP 7436145B2
Authority
JP
Japan
Prior art keywords
nucleic acid
expression
cells
cas9
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018563152A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517262A (ja
JP2019517262A5 (enExample
Inventor
ラヴァサール，フィリップ
マル，ジャック
セルゲーラ，シェ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Sorbonne Universite
Institut du Cerveau et de La Moelle Epiniere ICM
Original Assignee
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Sorbonne Universite
Institut du Cerveau et de La Moelle Epiniere ICM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Assistance Publique Hopitaux de Paris APHP, Sorbonne Universite, Institut du Cerveau et de La Moelle Epiniere ICM filed Critical Centre National de la Recherche Scientifique CNRS
Publication of JP2019517262A publication Critical patent/JP2019517262A/ja
Publication of JP2019517262A5 publication Critical patent/JP2019517262A5/ja
Priority to JP2022110001A priority Critical patent/JP2022133441A/ja
Application granted granted Critical
Publication of JP7436145B2 publication Critical patent/JP7436145B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2018563152A 2016-06-03 2017-06-02 Ｃａｓ９ヌクレアーゼをコードする核酸の食餌コントロール発現及びその使用 Active JP7436145B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022110001A JP2022133441A (ja) 2016-06-03 2022-07-07 Ｃａｓ９ヌクレアーゼをコードする核酸の食餌コントロール発現及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16172964 2016-06-03
EP16172964.5 2016-06-03
PCT/EP2017/063549 WO2017207797A1 (en) 2016-06-03 2017-06-02 Diet controlled expression of a nucleic acid encoding cas9 nuclease and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022110001A Division JP2022133441A (ja) 2016-06-03 2022-07-07 Ｃａｓ９ヌクレアーゼをコードする核酸の食餌コントロール発現及びその使用

Publications (3)

Publication Number Publication Date
JP2019517262A JP2019517262A (ja) 2019-06-24
JP2019517262A5 JP2019517262A5 (enExample) 2020-07-02
JP7436145B2 true JP7436145B2 (ja) 2024-02-21

Family

ID=56148119

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018563152A Active JP7436145B2 (ja) 2016-06-03 2017-06-02 Ｃａｓ９ヌクレアーゼをコードする核酸の食餌コントロール発現及びその使用
JP2022110001A Pending JP2022133441A (ja) 2016-06-03 2022-07-07 Ｃａｓ９ヌクレアーゼをコードする核酸の食餌コントロール発現及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022110001A Pending JP2022133441A (ja) 2016-06-03 2022-07-07 Ｃａｓ９ヌクレアーゼをコードする核酸の食餌コントロール発現及びその使用

Country Status (11)

Country Link
US (2) US20190185832A1 (enExample)
JP (2) JP7436145B2 (enExample)
KR (1) KR102317622B1 (enExample)
CN (2) CN116064534A (enExample)
AU (1) AU2017275769B2 (enExample)
BR (1) BR112018074930A2 (enExample)
CA (1) CA3025591A1 (enExample)
IL (1) IL263291B2 (enExample)
RU (1) RU2771383C2 (enExample)
SG (1) SG11201810772XA (enExample)
WO (1) WO2017207797A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3823995A4 (en) * 2018-08-01 2022-05-04 The Regents of the University of Colorado, a body corporate PROGRAMMABLE THERAPEUTIC FUSOGENE SECRETED GECTOSOME DESIGNER VESICLES FOR MACROMOLECULE RELEASE AND GENOME MODIFICATION
CN112442528B (zh) * 2019-08-30 2022-08-12 深圳华大基因股份有限公司 Loxhd1基因突变体及其应用
CN114058689B (zh) * 2020-07-30 2024-08-20 南京市妇幼保健院 一种基因突变检测试剂盒及其应用
CN119894540A (zh) * 2022-07-05 2025-04-25 营养治疗基因公司 人类t或nk细胞中转基因的受控表达用于细胞免疫疗法
WO2024100176A1 (en) * 2022-11-10 2024-05-16 Nutritheragene Controlled gene therapy of ocular diseases
CN116732043B (zh) * 2023-08-10 2023-10-17 四川省医学科学院·四川省人民医院 一种突变基因及其白内障筛查的用途与白内障筛查试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140322184A1 (en) 2011-11-08 2014-10-30 Institut National De La Recherche Agronomique (Inra) Inducible expression cassette, and uses thereof
WO2015089462A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing
WO2015089465A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2713243T3 (es) * 2012-12-06 2019-05-20 Sigma Aldrich Co Llc Modificación y regulación del genoma basada en CRISPR
US20150098954A1 (en) * 2013-10-08 2015-04-09 Elwha Llc Compositions and Methods Related to CRISPR Targeting

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140322184A1 (en) 2011-11-08 2014-10-30 Institut National De La Recherche Agronomique (Inra) Inducible expression cassette, and uses thereof
WO2015089462A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing
WO2015089465A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ＮＡＴＵＲＥ ＢＩＯＴＥＣＨＮＯＬＯＧＹ，Ｖｏｌ．３３， Ｎｏ．４，２０１５年，ｐ．３９０－３９４
ＮＡＴＵＲＥ ＣＨＥＭＩＣＡＬ ＢＩＯＬＯＧＹ，２０１５年，Ｖｏｌ．１１， Ｎｏ．３，ｐ．１９８－２００
ＳＣＩＥＮＣＥ ＳＩＧＮＡＬＩＮＧ，２０１５年，ＶＯＬ：８， ＮＲ：３７４ （ＲＳ５），ＰＡＧＥ（Ｓ）：１－１０

Also Published As

Publication number Publication date
IL263291B1 (en) 2023-03-01
BR112018074930A2 (pt) 2019-03-12
KR102317622B1 (ko) 2021-10-26
RU2018142174A (ru) 2020-07-10
US20190185832A1 (en) 2019-06-20
AU2017275769A1 (en) 2018-12-20
SG11201810772XA (en) 2018-12-28
CA3025591A1 (en) 2017-12-07
AU2017275769B2 (en) 2023-04-13
RU2771383C2 (ru) 2022-05-04
CN116064534A (zh) 2023-05-05
US20230313161A1 (en) 2023-10-05
JP2022133441A (ja) 2022-09-13
JP2019517262A (ja) 2019-06-24
KR20190031230A (ko) 2019-03-25
IL263291A (en) 2018-12-31
CN109906271A (zh) 2019-06-18
RU2018142174A3 (enExample) 2020-09-30
IL263291B2 (en) 2023-07-01
WO2017207797A1 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
JP7436145B2 (ja) Ｃａｓ９ヌクレアーゼをコードする核酸の食餌コントロール発現及びその使用
US20250082778A1 (en) Rna guided eradication of human jc virus and other polyomaviruses
US20240035049A1 (en) Methods and compositions for modulating a genome
US20230242899A1 (en) Methods and compositions for modulating a genome
Mohanna et al. LNP-mediated delivery of CRISPR RNP for wide-spread in vivo genome editing in mouse cornea
CN107949424B (zh) Tat诱导的基于crispr/核酸内切酶的基因编辑
US10709797B2 (en) Isolation of extracellular vesicles (EVs) from red blood cells for gene therapy
Duarte et al. Genome editing for CNS disorders
JP6875500B2 (ja) Ｃａｓ９タンパク質およびガイドＲＮＡを含む眼疾患治療用薬学組成物
US20250099554A1 (en) Compositions and methods of fas inhibition
JP2023527464A (ja) ＳＡＲＭ１の両対立ｋ遺伝子ノックアウト
Altay et al. Gene regulatory and gene editing tools and their applications for retinal diseases and neuroprotection: From proof-of-concept to clinical trial
US20250312376A1 (en) Compositions and methods for modulating a genome in t cells, induced pluripotent stem cells, and respiratory epithelial cells
Dulak Gene therapy. The legacy of Wacław Szybalski
JP7393770B2 (ja) ゲノム編集による２つの最も高頻度に見られるｕｓｈ２ａ突然変異の修正
US20240002818A1 (en) Mammalian mobile element compositions, systems and therapeutic applications
WO2021150987A1 (en) Novel erythroid specific enhancers and uses thereof
EP3464574A1 (en) Diet controlled expression of a nucleic acid encoding cas9 nuclease and uses thereof
Taebi et al. Genetic engineering in hematopoietic stem cells for β-Hemoglobinopathies treatment: advances, challenges, and clinical translation
WO2007047706A2 (en) Methods and compositions for regulating gene expression
US20240175035A1 (en) Compositions and methods for treating hypercholesterolemia
US20240307554A1 (en) Transduction buffer
Lopes et al. Gene Editing for ATXN3 Inactivation in Machado-Joseph disease: CRISPR-Cas9 as a Therapeutic Alternative to TALEN-Induced Toxicity
EP4373950A1 (en) Erythroid specific enhancers
WO2025212757A2 (en) Cas enabled targeted transposition

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210525

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211012

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220308

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220707

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20220719

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220719

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240208

R150 Certificate of patent or registration of utility model

Ref document number: 7436145

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150